GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zynerba Pharmaceuticals Inc (NAS:ZYNE) » Definitions » Cash Flow from Operations

Zynerba Pharmaceuticals (Zynerba Pharmaceuticals) Cash Flow from Operations : $-31.64 Mil (TTM As of Jun. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Zynerba Pharmaceuticals Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Jun. 2023, Zynerba Pharmaceuticals's Net Income From Continuing Operations was $-10.78 Mil. Its Depreciation, Depletion and Amortization was $0.07 Mil. Its Change In Working Capital was $1.52 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $0.77 Mil. And its Cash Flow from Others was $-0.00 Mil. In all, Zynerba Pharmaceuticals's Cash Flow from Operations for the three months ended in Jun. 2023 was $-8.42 Mil.


Zynerba Pharmaceuticals Cash Flow from Operations Historical Data

The historical data trend for Zynerba Pharmaceuticals's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zynerba Pharmaceuticals Cash Flow from Operations Chart

Zynerba Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -32.40 -34.82 -41.31 -33.46 -23.03

Zynerba Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.88 -9.66 -5.69 -7.88 -8.42

Zynerba Pharmaceuticals Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Zynerba Pharmaceuticals's Cash Flow from Operations for the fiscal year that ended in Dec. 2022 is calculated as:

Zynerba Pharmaceuticals's Cash Flow from Operations for the quarter that ended in Jun. 2023 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zynerba Pharmaceuticals  (NAS:ZYNE) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Zynerba Pharmaceuticals's net income from continuing operations for the three months ended in Jun. 2023 was $-10.78 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Zynerba Pharmaceuticals's depreciation, depletion and amortization for the three months ended in Jun. 2023 was $0.07 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Zynerba Pharmaceuticals's change in working capital for the three months ended in Jun. 2023 was $1.52 Mil. It means Zynerba Pharmaceuticals's working capital increased by $1.52 Mil from Mar. 2023 to Jun. 2023 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Zynerba Pharmaceuticals's cash flow from deferred tax for the three months ended in Jun. 2023 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Zynerba Pharmaceuticals's cash from discontinued operating Activities for the three months ended in Jun. 2023 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Zynerba Pharmaceuticals's asset impairment charge for the three months ended in Jun. 2023 was $0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Zynerba Pharmaceuticals's stock based compensation for the three months ended in Jun. 2023 was $0.77 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Zynerba Pharmaceuticals's cash flow from others for the three months ended in Jun. 2023 was $-0.00 Mil.


Zynerba Pharmaceuticals Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Zynerba Pharmaceuticals's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Zynerba Pharmaceuticals (Zynerba Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
80 West Lancaster Avenue, Suite 300, Devon, PA, USA, 19333
Zynerba Pharmaceuticals Inc is a pharmaceutical company that is focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product pipeline consists of Zygel which is a pharmaceutically-produced CBD, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
Executives
Kenneth T Jones officer: See Remarks C/O ZYNERBA PHARMACEUITCALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Brian Rosenberger officer: VP, Commercial & Business Dev. C/O ZYNERBA PHARMACEUTICALS, INC., 80 WEST LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Terri B Sebree officer: President ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
James E Fickenscher officer: Chief Financial Officer C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19087
Armando Anido director, officer: Chairman & Chief Exec. Officer 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Kenneth I Moch director 68 WILLOW AVE, LARCHMONT NY 10538
Warren D Cooper director NUTRITION 21 INC, 4 MANHATTANVILLE ROAD, PURCHASE NY 10577
Pamela Stephenson director C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
John P. Butler director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Daniel L Kisner director 2292 FARADAY AVENUE, CARLSBAD CA 92008
William J Federici director 530 HERMAN O. WEST DRIVE, EXTON PA 19341
Albert P Parker officer: Chief Legal Officer C/O ONCOCYTE CORPORATION, 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Suzanne M. Hanlon officer: Sec, General Counsel & VP HR 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Michael Rapp 10 percent owner 712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019
Thomas L Harrison director

Zynerba Pharmaceuticals (Zynerba Pharmaceuticals) Headlines

From GuruFocus